Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025 Pharmacy Phase III REDEFINE trials at #ADA2025 reveal that once weekly CagriSema (semaglutide + cagrilintide) delivers impressive weight loss in adults without diabetes and in those with type 2 #diabetes, alongside favorable Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine PDF) Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta Analysis Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing